{"DataElement":{"publicId":"6483078","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma Subtype Basis MYC Arrangement Type","preferredDefinition":"The arrangement type of Cytogenetic aberrations in the gene are involved in cellular transformation and are associated with a variety of hematopoietic tumors, leukemias and lymphomas.","longName":"DLBCL_SUB_MYC_TP","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6033044","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma Subtype Basis","preferredDefinition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma._A group forming a type within a larger type._The fundamental assumptions underlying an explanation or a relation that provide the foundation for something.","longName":"6033041v1.0:6033042v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"6033041","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma Subtype","preferredDefinition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.:A group forming a type within a larger type.","longName":"C8851:C25696","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma","conceptCode":"C8851","definition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Subtype","conceptCode":"C25696","definition":"A group forming a type within a larger type.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F0FDC41-9C83-2EE5-E053-F662850A207E","latestVersionIndicator":"Yes","beginDate":"2017-11-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-28","modifiedBy":"ONEDATA","dateModified":"2017-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6033042","version":"1","preferredName":"Basis","preferredDefinition":"The fundamental assumptions underlying an explanation or a relation that provide the foundation for something.","longName":"C25430","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Basis","conceptCode":"C25430","definition":"The fundamental assumptions underlying an explanation or a relation that provide the foundation for something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F0FDC41-9C91-2EE5-E053-F662850A207E","latestVersionIndicator":"Yes","beginDate":"2017-11-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-28","modifiedBy":"ONEDATA","dateModified":"2017-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F0FDC41-9CA2-2EE5-E053-F662850A207E","latestVersionIndicator":"Yes","beginDate":"2017-11-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-28","modifiedBy":"NYCHM","dateModified":"2018-02-12","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6483077","version":"1","preferredName":"MYC Arrangement Type","preferredDefinition":"This gene plays a role in cell cycle progression and apoptosis. Cytogenetic aberrations in the gene are involved in cellular transformation and are associated with a variety of hematopoietic tumors, leukemias and lymphomas._The spatial property of the way in which something is placed. Something distinguishable as an identifiable class based on common qualities._","longName":"6483077v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Germinal center B-cell","valueDescription":"Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma","ValueMeaning":{"publicId":"3185303","version":"1","preferredName":"GCB","longName":"3185303v1.00","preferredDefinition":"A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile.  It represents approximately 50% of diffuse large B-cell lymphomas, and is characterized by the expression of CD10, BCL-6, A-myb, and LMO2 genes, BCL-2 translocation, and c-REL amplification.  Morphologically, the vast majority of these lymphomas are centroblastic and a small minority are immunoblastic (ratio20:1).  Patients with this type of diffuse large B-cell lymphoma have a more favorable outcome, with a 5-year survival rate of 60% and a median survival of 10 years.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","conceptCode":"C36080","definition":"A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile.  It represents approximately 50% of diffuse large B-cell lymphomas, and is characterized by the expression of CD10, BCL-6, A-myb, and LMO2 genes, BCL-2 translocation, and c-REL amplification.  Morphologically, the vast majority of these lymphomas are centroblastic and a small minority are immunoblastic (ratio20:1).  Patients with this type of diffuse large B-cell lymphoma have a more favorable outcome, with a 5-year survival rate of 60% and a median survival of 10 years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A602691-7F26-B189-E040-BB89AD437FA7","latestVersionIndicator":"Yes","beginDate":"2011-01-21","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-01-21","modifiedBy":"FINCHAMB","dateModified":"2023-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"785B3E70-58E2-55FC-E053-F662850AFEC8","beginDate":"2018-10-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-16","modifiedBy":"ONEDATA","dateModified":"2018-10-16","deletedIndicator":"No"},{"value":"Activated B-cell","valueDescription":"Activated B-Cell-Like Diffuse Large B-Cell Lymphoma","ValueMeaning":{"publicId":"3185301","version":"1","preferredName":"Non-GCB","longName":"3185301v1.00","preferredDefinition":"A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile.  It represents approximately 30% of diffuse large B-cell lymphomas, and is characterized by the expression of CD44, PKCbeta1, Cyclin D2, BCL-2, and IRF4/MUM1 genes.  Morphologically, these lymphomas are either centroblastic or immunoblastic (ratio 2:1).  Patients with this type of diffuse large B-cell lymphoma are reported to have a less favorable outcome compared to those with a germinal center B-cell expression profile, with a 5-year survival rate of 35% and a median survival of 2 years.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma Activated B-Cell Type","conceptCode":"C36081","definition":"A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile.  It represents approximately 30% of diffuse large B-cell lymphomas, and is characterized by the expression of CD44, PKCbeta1, Cyclin D2, BCL-2, and IRF4/MUM1 genes.  Morphologically, these lymphomas are either centroblastic or immunoblastic (ratio 2:1).  Patients with this type of diffuse large B-cell lymphoma are reported to have a less favorable outcome compared to those with a germinal center B-cell expression profile, with a 5-year survival rate of 35% and a median survival of 2 years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A602691-7F00-B189-E040-BB89AD437FA7","latestVersionIndicator":"Yes","beginDate":"2011-01-21","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-01-21","modifiedBy":"FINCHAMB","dateModified":"2023-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"785B3E70-58F6-55FC-E053-F662850AFEC8","beginDate":"2018-10-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-16","modifiedBy":"ONEDATA","dateModified":"2018-10-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6483079","version":"1","preferredName":"MYC Gene Arrangement Type","preferredDefinition":"This gene plays a role in cell cycle progression and apoptosis. Cytogenetic aberrations in the gene are involved in cellular transformation and are associated with a variety of hematopoietic tumors, leukemias and lymphomas.:The spatial property of the way in which something is placed.:Something distinguishable as an identifiable class based on common qualities.","longName":"C16887:C61532:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MYC Gene","conceptCode":"C16887","definition":"This gene plays a role in cell cycle progression and apoptosis. Cytogenetic aberrations in the gene are involved in cellular transformation and are associated with a variety of hematopoietic tumors, leukemias and lymphomas.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Arrangement","conceptCode":"C61532","definition":"The spatial property of the way in which something is placed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"785BBCCB-D740-0BD8-E053-F662850A4B74","latestVersionIndicator":"Yes","beginDate":"2018-10-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-16","modifiedBy":"ONEDATA","dateModified":"2018-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"785B3E70-58C2-55FC-E053-F662850AFEC8","latestVersionIndicator":"Yes","beginDate":"2018-10-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-16","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeDescription":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"If yes, which MYC arrangement","type":"Preferred Question Text","description":"If yes, which MYC arrangement are present?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"785BAAC9-2789-2B4D-E053-F662850AEC5A","latestVersionIndicator":"Yes","beginDate":"2018-10-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-16","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeDescription":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}